Adjunctive pharmacotherapy for coronary interventions—time to read the writing on the wall

References

• Lincoff A. M., Bittl J. A., Harrington R. A., Feit F., Kleiman N. S., Jackman J. D., et al. REPLACE‐2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE‐2 randomized trial. JAMA 2003; 289: 853–63
   PubMed Web of Science ®Google Scholar
• Brener S. J., Moliterno D. J., Lincoff A. M., Steinhubl S. R., Wolski K. E., Topol E. J. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110: 994–8
   PubMed Web of Science ®Google Scholar
• Kandzari D. E., Berger P. B., Kastrati A., Steinhubl S. R., Mehilli J., Dotzer F., et al. ISAR‐REACT Study Investigators. Influence of treatment duration with a 600‐mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44: 2133–6
   PubMed Web of Science ®Google Scholar
• ACUITY‐ Presented at the ACC meeting 2006. Posted on the American College of Cardiology Site: http://www.cardiosource.com/trialfocus/tfc_acuity.asp
   Google Scholar
• Moses J. W., Leon M. B., Popma J. J., Fitzgerald P. J., Holmes D. R., O'Shaughnessy C., et al. SIRIUS Investigators. Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Stone G. W., Ellis S. G., Cox D. A., Hermiller J., O'Shaughnessy C., Mann J. T., et al. TAXUS‐IV Investigators. A polymer‐based, paclitaxel‐eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31
   PubMed Web of Science ®Google Scholar
• Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G. M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug‐eluting stents. JAMA 2005; 293: 2126–30
   PubMed Web of Science ®Google Scholar
• Milkovich G., Gibson G. Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60: S15–21
   PubMed Web of Science ®Google Scholar
• Wolfe M. W., Roubin G. S., Schweiger M., Isner J. M., Ferguson J. J., Cannon A. D., et al. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Heparin Registry Investigators. Circulation 1995; 92: 311–9
   PubMed Web of Science ®Google Scholar
• STEEPLE‐ Presentation. Presented on the 6th of September 2005, in ‘Late breaking trials’ session by Montalescot G., Posted in The European Society of Cardiology Site (www.escardio.org) and at tctmd.com
   Google Scholar
• Exaire J. E., Tcheng J. E., Kereiakes D. J., Kleiman N. S., Applegate R. J., Moliterno D. J., ELECT Investigators. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv 2005; 64: 369–72
   PubMed Web of Science ®Google Scholar
• Moscucci M., Fox K. A., Cannon C. P., Klein W., Lopez‐Sendon J., Montalescot G., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815–23
   PubMed Web of Science ®Google Scholar
• Alexander K. P., Chen A. Y., Roe M. T., Newby L. K., Gibson C. M., Allen‐LaPointe N. M., , CRUSADE Investigators, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non‐ST‐segment elevation acute coronary syndromes. JAMA 2005; 294: 3108–16
   PubMed Web of Science ®Google Scholar
• Huynh T., Piazza N., DiBattiste P. M., Snapinn S. M., Wan Y., Pharand C., et al. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high‐risk acute coronary syndromes: insights from the PRISM‐PLUS study. Int J Cardiol 2005; 100: 73–8
   PubMed Web of Science ®Google Scholar
• MICHELANGELO OASIS 5 Steering Committee. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)‐5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non‐ST‐segment elevation acute coronary syndromes. Am Heart J 2005; 150: 1107
   PubMed Web of Science ®Google Scholar
• OASIS V‐ Presentation. Presented on the 6th of September 2005, in ‘Late beaking trials’ session., Posted in The European Society of Cardiology Site (www.escardio.org)
   Google Scholar
• Ferguson J. J., Califf R. M., Antman E. M., Cohen M., Grines C. L., Goodman S., , SYNERGY Trial Investigators, et al. Enoxaparin vs unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54
   PubMed Web of Science ®Google Scholar
• Horwitz P. A., Berlin J. A., Sauer W. H., Laskey W. K., Krone R. J., Kimmel S. E., Registry Committee of the Society for Cardiac Angiography Interventions. Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad‐based practice (results from the Society for Cardiac Angiography and Interventions Registry). Am J Cardiol 2003; 91: 803–6
   PubMed Web of Science ®Google Scholar
• Popma J. J., Berger P., Ohman E. M., Harrington R. A., Grines C., Weitz J. I. Antithrombotic therapy during percutaneous coronary intervention: the SeventhACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 576S–99S
   PubMed Web of Science ®Google Scholar
• Silber S., Albertsson P., Aviles F. F., Camici P. G., Colombo A., Hamm C., , Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology, et al. Guidelines for percutaneous coronary interventions. The Task Force forPercutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804–47
   PubMed Web of Science ®Google Scholar
• Smith S., Feldman T. E., Hirshfeld J. W Jr., Jacobs A. K., Kern M. J., King S. B 3rd., , ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166–286
   PubMed Web of Science ®Google Scholar
• Kastrati A., Mehilli J., Neumann F. J., Dotzer F., ten Berg J., Bollwein H., et al. Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR‐REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR‐REACT 2 randomized trial. JAMA 2006; 295: 1531–8
   PubMed Web of Science ®Google Scholar
• Mehilli J., Kastrati A., Schuhlen H., Dibra A., Dotzer F., von Beckerath N., , Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR‐SWEET) Study Investigators, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627–35
   PubMed Web of Science ®Google Scholar
• Gangasani S. R., O'Neill W. W., Grines C. L. Role of prolonged intravenous heparin in unstable angina patients prior to coronary angioplasty. J Interv Cardiol 2001; 14: 423–8
   PubMedGoogle Scholar
• Neumann F., Kastrati A., Pogatsa‐Murray G., et al. Evaluation of Prolonged Antithrombotic Pretreatment (‘Cooling‐Off’ Strategy) Before Intervention in Patients With Unstable Coronary Syndromes: A Randomized Controlled Trial. JAMA 2003; 290: 1593–9
   PubMed Web of Science ®Google Scholar
• Cragg D. R., Friedman H. Z., Almany S. L., Gangadharan V., Ramos R. G., Levine A. B., et al. Early hospital discharge after percutaneous transluminal coronary angioplasty. Am J Cardiol 1989; 64: 1270–4
   PubMed Web of Science ®Google Scholar
• Rabah M., Mason D., Muller D. W., Hundley R., Kugelmass A. D., Weiner B., et al. Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol 1999; 34: 461–7
   PubMed Web of Science ®Google Scholar
• Bathelor W. B., Mahaffey K. W., Berger P. B. Randomized placebo controlled trial of Enoxaparin after high risk coronary stenting. J Am Coll Cardiol 2001; 38: 1608–13
   PubMed Web of Science ®Google Scholar
• Karsch K. R., Preisack M. B., Baildon R., Eschenfelder V., Foley D., Garcia E. J., et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double‐blind, unfractionated heparin and placebo‐controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double‐Blind Unfractionated Heparin and Placebo‐Controlled Evaluation. J Am Coll Cardiol 1996; 28: 1437–43
   PubMed Web of Science ®Google Scholar
• Narins C. R., Hillegass W. B Jr., Nelson C. L., Tcheng J. E., Harrington R. A., Phillips H. R., et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667–71
   PubMed Web of Science ®Google Scholar
• Ferguson J. J., Dougherty K. G., Gaos C. M., Bush H. S., Marsh K. C., Leachman D. R. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23: 1061–5
   PubMed Web of Science ®Google Scholar
• McGarry T. F Jr., Gottlieb R. S., Morganroth J., Zelenkofske S. L., Kasparian H., Duca P. R., et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123: 1445–51
   PubMed Web of Science ®Google Scholar
• Frierson J. H., Dimas A. P., Simpfendorfer C. C., Miller M., Franco I. Is aggressive heparinization necessary for elective PCI?. Cathet Cardiovasc Diagn 1993; 30: 268–9
   PubMedGoogle Scholar
• Hillegass W. B., Brott B. C., Chapman G. D., Phillips H. R., Stack R. S., Tcheng J. E., et al. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. Am Heart J 2002; 144: 501–7
   PubMed Web of Science ®Google Scholar
• Vainer J., Fleisch M., Gunnes P., Ramamurthy S., Garachemani A., Kaufmann U. P., et al. Low‐dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996; 78: 964–6
   PubMed Web of Science ®Google Scholar
• Boccara A., Benamer H., Juliard J. M., Aubry P., Goy P., Himbert D., et al. A randomized trial of a fixed high dose vs a weight‐adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997; 18: 631–5
   PubMed Web of Science ®Google Scholar
• Koch K. T., Piek J. J., de Winter R. J., Mulder K., David G. K., Lie K. I. Short term (4 hours) observation after elective coronary angioplasty. Am J Cardiol 1997; 80: 1591–4
   PubMed Web of Science ®Google Scholar
• Tengiz I., Ercan E., Bozdemir H., Durmaz O., Gurgun C., Nalbantgil I. Six hour ambulation after elective coronary angioplasty and stenting with 7F guiding catheters and low dose heparin. Kardiol Pol 2003; 58: 93–7
   PubMedGoogle Scholar
• Kaluski E., Krakover R., Cotter G. Minimal heparinization in coronary angioplasty—how much heparin is really warranted?. Am J Cardiol 2000; 85: 953–6
   PubMed Web of Science ®Google Scholar
• Caussin C., Fsihi A., Ohanessian A., Jacq L., Rahal S., Lancelin B. Direct stenting with 3000 i.u. heparin. Int J Cardiovasc Intervent 2003; 5: 206–10
   PubMedGoogle Scholar
• Denardo S. J., Davis K. E., Reid P. R., Tcheng J. E. Efficacy and safety of minimal dose (< or = 1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol 2003; 91: 1–5
   PubMed Web of Science ®Google Scholar
• Denardo S. J., Davis K. E., Tcheng J. E. Elective percutaneous coronary intervention using broad‐spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 2005; 149: 138–44
   PubMed Web of Science ®Google Scholar
• Taguchi H., Kawarabayashi T., Tanaka A., Nishida Y., Sakamoto T., Tahara A., et al. Efficacy and safety of PTCA using brachial approach and low‐dose heparin. Catheter Cardiovasc Interv 2001; 54: 165–8
   PubMed Web of Science ®Google Scholar
• Mehran R., Aymong E. D., Ashby D. T., Fischell T., Whitworth H Jr., Siegel R., et al. Safety of an aspirin‐alone regimen after intracoronary stenting with a heparin‐coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Circulation 2003; 108: 1078–83
   PubMed Web of Science ®Google Scholar
• Godon P., Rioufol G., Finet G., Chirossel P., de Gevigney G. D., Roriz R., et al. Efficacy and safety of low‐dose heparin (30 IU/kg) during coronary angioplasty. Arch Mal Coeur Vaiss 2001; 94: 984–8
   PubMedGoogle Scholar
• Bittl J. A., Ahmed W. H. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol 1998; 82: 50P–6P
   PubMed Web of Science ®Google Scholar
• Tolleson T. R., O'Shea J. C., Bittl J. A., Hillegass W. B., Williams K. A., Levine G., et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003; 41: 386–93
   PubMed Web of Science ®Google Scholar
• Chew D. P., Bhatt D. L., Lincoff A. M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001 20; 103: 961–6
   PubMed Web of Science ®Google Scholar
• Kastrati A., Mehilli J., Schuhlen H., Dirschinger J., Dotzer F., ten Berg J. M., , Intracoronary Stenting and Antithrombotic Regimen‐Rapid Early Action for Coronary Treatment Study Investigators, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232–8
   PubMed Web of Science ®Google Scholar
• Morice M. C., Colombo A., Meier B., Serruys P., Tamburino C., Guagliumi G., , REALITY Trial Investigators, et al. Sirolimus‐ vs paclitaxel‐eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895–904
   PubMed Web of Science ®Google Scholar
• ENDEAVOR II—Presented by Dr William Wijns at the March 2005 ACC Annual Scientific Session, Orlando, FL. Posted at cardiosource.com/clinicaltrials & tctmd.com
   Google Scholar
• Windecker S., Remondino A., Eberli F. R., Juni P., Raber L., Wenaweser P., et al. Sirolimus‐Eluting and Paclitaxel‐Eluting Stents for Coronary Revascularization. N Engl J Med 2005; 353: 653–62
   PubMed Web of Science ®Google Scholar
• ENDEAVOR III—Presented by Dr David E. Kandzari at TCT 2005, Washington, DC. Posted at cardiosource.com/clinicaltrials & tctmd.com
   Google Scholar
• Stone G. W., Ellis S. G., Cannon L., Mann J. T., Greenberg J. D., Spriggs D., , TAXUS V Investigators, et al. Comparison of a polymer‐based paclitaxel‐eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215–23
   PubMed Web of Science ®Google Scholar
• E‐Cypher Registry Data‐ Posted at tctmd.com
   Google Scholar